Intract Pharma

An oral drug delivery licensing and product development company offering a range of proprietary formulation technologies for advanced therapeutics.

[Intract Pharma @intractpharma]

We are delighted to announce that we've been awarded an @innovateuk grant to manufacture an oral antibody formulation using #Soteria in partnership with @ukCPI, @Pharmidex and @QuayPharma.

Read more here: https://t.co/8F5RqH6oFE

[Intract Pharma @intractpharma]

An innovative capsule could take the gold-standard treatment for #CrohnsDisease – infliximab – out of hospital and into patients’ homes for the first time.

Find out about how this treatment can benefit Louise Barker from @ukCPI at: https://t.co/zSy8YvDxIs
#WorldIBDDay

[Intract Pharma @intractpharma]

Scientist or Senior Scientist, Oral Protein Formulation job with Intract Pharma

https://t.co/QpjPgF8cLd

[Euronews Next @euronewsnext]

What will the future of healthcare look like? How will technology impact the way you manage your health?
Chief Digital Officer at @sanofi shares his predictions 💡👨‍⚕️

https://t.co/tKvHQONjbc

[Intract Pharma @intractpharma]

April 22, 2021 | Featured

Intract Pharma and NIBEC Enter into an Agreement to Develop a Novel Oral Peptide Therapy for Treatment of Ulcerative Colitis.

https://t.co/nqkKw6AEZr

[Intract Pharma @intractpharma]

April 01, 2021 | Featured

Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals to Evaluate Oral delivery of Monoclonal Antibodies for Treatment of Chronic Gastrointestinal Diseases

[Intract Pharma @intractpharma]

August 20, 2020 | Featured

Intract Pharma Limited and Celltrion Group announce collaboration for development of oral Infliximab.

https://t.co/wLqbxEbdN8

[Intract Pharma @intractpharma]

May 26, 2020 | Featured

Intract Pharma and N&S Pharmacy Investment announce partnership to develop orally-delivered GLP-1R agonist peptide therapeutic.

https://t.co/5e57iJnGoE

[Intract Pharma @intractpharma]

May 05, 2020 | Featured

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics.

https://t.co/OkLwXE9GgT

[Intract Pharma @intractpharma]

October 24, 2019 | Featured

Intract’s Soteria® and Phloral® Technologies Highlighted Among Revolutionary Approaches to Crack Oral Biologics Delivery Challenge

https://t.co/LVxclwdQ3y

[Intract Pharma @intractpharma]

May 07, 2019 | Phloral

Carus Animal Health and Intract Pharma Enter Agreement to Develop Novel Drug Delivery Technology.

[Intract Pharma @intractpharma]

5th April 2019 London, UK and Tokyo, Japan: Intract Pharma Ltd and Neopharma Japan Co. Ltd, have announced entry into a collaboration to develop a novel therapeutic product for treatment of gastrointestinal diseases using Intract’s proprietary drug delivery technologies.

[Intract Pharma @intractpharma]

London, England, 27th March 2019.

Intract Pharma has announced the launch of a first product incorporating its colon targeting technology, Phloral®. The product - called Yaldigo®/Asacol 1600 has been created and is marketed by Tillotts Pharma AG, Switzerland. @tillotts_pharma

[Basit Research Group @BasitResearch]

Great talk by Vipul Yadav from @intractpharma on their innovative #Phloral and #Soteria oral drug delivery technologies for the delivery of antibodies! @APS_PharmSci #PharmSci2019

[Carus Animal Health @carus_ah]

Our partners @intractpharma are working on some exciting drug delivery technologies including enabling biologics, like monoclonal antibodies, to be given as tablets rather than injectables. https://t.co/bHkW5Uu4tm

[Carus Animal Health @carus_ah]

Medication conundrums - @intractpharma are creating solutions to gut metabolism with innovative new oral drug delivery technology #veterinary #veterinarymedicine #vetinnovation #vetmed
https://t.co/MxZ1n80Xbd

[Intract Pharma @intractpharma]

Intract has entered into an agreement with @carus_ah to develop new therapies for the Veterinary Market

Read More here:

https://t.co/kdVedXMfIj

#AnimalHealth #Veterinarian

[Intract Pharma @intractpharma]

We are proud to announce that we've entered into a collaboration with @Neopharma1 to develop a novel treatment for #Gastrointestinal diseases.

Read more here: https://t.co/3EEZLQFMdy

[Intract Pharma @intractpharma]

Market launch of a first Phloral® coated product, read more here:

https://t.co/lFJ4ZWiUUd

[UCL School of Pharmacy @School_Pharmacy]

Our colleagues @intractpharma , a spin out company from the @School_Pharmacy, have successfully been awarded over £1.4million in funding from @innovateuk to develop a scalable manufacturing process for novel oral antibody products. Read more: https://t.co/KwvBHNKs2B

[Intract Pharma @intractpharma]

Head on over to https://t.co/jur3aUpr76 to see our new Phloral® and Soteria® videos!